Molecule
Glatiramer is a prescription medicine indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults. MedsAcross supplies Glatiramer for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
From the regulator-approved product information. Each section names its source.
COPAXONE is indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults.
Source: US FDA prescribing information
The mechanism(s) by which glatiramer acetate exerts its effects in patients with MS are not fully understood. However, glatiramer acetate is thought to act by modifying immune processes that are believed to be responsible for the pathogenesis of MS. This hypothesis is supported by findings of studies that have been carried out to explore the pathogenesis of experimental autoimmune encephalomyelitis, a condition induced in animals through immunization against central nervous system derived material containing myelin and often used as an experimental animal model of MS. Studies in animals and in vitro systems suggest that upon its administration, glatiramer acetate-specific suppressor T-cells are induced and activated in the periphery. Because glatiramer acetate can modify immune functions, concerns exist about its potential to alter naturally-occurring immune responses.
Source: US FDA prescribing information
For subcutaneous injection only, doses are not interchangeable. COPAXONE 20 mg/mL per day. COPAXONE 40 mg/mL three times per week. Before use, allow the solution to warm to room temperature
Source: US FDA prescribing information
COPAXONE is contraindicated in patients with known hypersensitivity to glatiramer acetate or mannitol. Reactions have included anaphylaxis. Known hypersensitivity to glatiramer acetate or mannitol
Source: US FDA prescribing information
Boxed warning (anaphylactic reactions): Cases of life-threatening and fatal anaphylaxis have been reported with COPAXONE. Anaphylaxis can occur at any time following initiation of therapy, from as early as after the first dose, up to years following initiation of therapy. Immediate Post-Injection Reaction (flushing, chest pain, palpitations, tachycardia, anxiety, dyspnea, throat constriction, and/or urticaria), may occur within seconds to minutes after injection and are generally transient and self-limiting. Chest pain, usually transient. Lipoatrophy and skin necrosis may occur. Instruct patients in proper injection technique and to rotate injection sites. COPAXONE can modify immune response. Hepatic Injury: if signs or symptoms of hepatic dysfunction occur, consider discontinuing COPAXONE.
Source: US FDA prescribing information
The following serious adverse reactions are described elsewhere in the labeling: Anaphylactic Reactions Immediate Post-Injection Reaction Chest Pain Lipoatrophy and Skin Necrosis Potential Effects on Immune Response Hepatic Injury In controlled studies of COPAXONE 20 mg/mL, most common adverse reactions (≥10% and ≥1.5 times higher than placebo) were: injection site reactions, vasodilatation, rash, dyspnea, and chest pain. In a controlled study of COPAXONE 40 mg/mL, most common adverse reactions (≥10% and ≥1.5 times higher than placebo) were: injection site reactions
Source: US FDA prescribing information
Store COPAXONE refrigerated at 2°C to 8°C (36°F to 46°F). If needed, the patient may store COPAXONE at room temperature, 15°C to 30°C (59°F to 86°F), for up to one month, but refrigeration is preferred. Do not freeze COPAXONE. If a COPAXONE syringe freezes, it should be discarded.
Source: US FDA prescribing information
For healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
6 presentations of Glatiramer, sorted by availability.
| Medicine | Manufacturer | Register | Availability |
|---|---|---|---|
| Glatiramer 20 mg/1 mL injectionSubcutaneous Cold chainGeneric name | — | US FDA | Available on request |
| Glatiramer 40 mg/1 mL injectionSubcutaneous Cold chainGeneric name | — | US FDA | Available on request |
| Glatopa 20 mg/1 mL injectionSubcutaneous Cold chain | Sandoz | US FDA | Available on request |
| Glatopa 40 mg/1 mL injectionSubcutaneous Cold chain | Sandoz | US FDA | Available on request |
| Copaxone 40 mg/1 mL injectionSubcutaneous Cold chain | Teva Neuroscience | US FDA | Available on request |
| Copaxone 20 mg/1 mL injectionSubcutaneous Cold chain | Teva Neuroscience | US FDA | Available on request |
2 brand names across 1 markets.
Approval facts from US FDA, EMA and CDSCO data, and registration status by country where we hold register data.
| Register | Status | Source |
|---|---|---|
| US FDA | First approved 20 December 1996 | Drugs@FDA |
| EU (EMA) | Not recorded | — |
| India (CDSCO) | Not yet confirmed against CDSCO approval lists | — |
| United States | Registered | US FDA (NDC directory, openFDA)Checked 12 November 2026 |
Yes, on request. MedsAcross lists 6 presentations of Glatiramer and sources them for licensed hospitals, importers and physicians against valid import documents.
The catalogue lists 2 brand names for Glatiramer, including Copaxone, Glatopa.
Yes. The US FDA first approved Glatiramer on 20 December 1996, according to Drugs@FDA.
At least one listed presentation of Glatiramer must be kept cold, so it is shipped in temperature-controlled packaging. Check the storage line on each presentation.
Tell us the strength, quantity and destination country. Our team replies with availability, lead time and the import documents needed.